Gallbladder cancer is a rare tumor with an extremely poor prognosis. 5-year survival is around 10% and has not significantly improved in the past decades. Curation is only possible through radical resection of the tumor. Due to a combination of locally aggressive tumour growth and nonspecific symptoms, the tumour is frequently diagnosed in an advanced stage and only 10-20% of tumours are ameniable to resection after diagnosis.
Due to the rarity of gallbladder cancer, little is known about chemotherapy and radiotherapy. Randomised evidence is lacking and international treatment guidelines are mainly based on a combination of retrospective research and expert opinion.
The aim of the TULYP study is to determine the optimal treatment for patients with gallbladder cancer through means of prospective registration. The aim of the TULYP study is to improve the quality of life and survival of patients with gallbladder cancer.
All patients with a (suspected) diagnosis of gallbladder cancer are eligible for inclusion in the TULYP study. Patients in which gallbladder cancer is diagnosed incidentally after cholecystectomy for another indication are also eligible for inclusion.
In The TULYP study, data on patients with gallbladder cancer will be recorded prospectively. Decisions regarding treatment will remain at the discretion of the treating physician in the local hospital. Participants will therefore be treated according to current guidelines. Participation in the study does not require any additional effort from the treating physician. Participation in the study does not require any additional effort from the treating physician. In all participating centers the local coordinator will enlist potential participants with the coordinating investigator. The coordinating investigator will contact the patient or treating physician in order to provide the study information and to obtain informed consent.
The following dated will be collected in the TULYP study; patient characteristics, symptoms during presentation and gollow-up, findings during follow-up appointments, results of imaging studies, surgical procedures and any complications, pathology reports, data on chemo- and radiotherapy, follow-up duration and survival.
Additionally, data on symptomatology and quality of life will be collected through (voluntary) questionnaires. Participation in the questionnaires is voluntary and not required in order to participate in the study. All data will be collected periodically by the coordinating investigator and will be entered into a secure, online database.
Do you have any questions or would you like to get involved? Send an e-mail to the coordinating investigator via email@example.com